How Does Pfizer Stock Stack Up Against Its Peers?
Pfizer‘s stock has largely underperformed peers over the past year, but how does it truly measure up against rivals scaling in new healthcare frontiers? A closer look reveals moderate profitability and growth, alongside a competitive valuation. However, significant upside remains constrained if faster-growing biotech and specialty pharma pure-plays continue to capture market momentum.
- PFE’s 24.6% operating margin, high yet trailing LLY’s 43.0%, suggests differing product mix profitability or cost structures.
- PFE’s 3.9% revenue growth, low and behind JNJ, ABBV, LLY, signals pipeline challenges or patent expirations, despite outpacing MRK, BMY.
- PFE’s 6.4% stock gain and 15.0 PE, weaker than JNJ, MRK, ABBV, LLY, reflects investor caution on future growth or pipeline strength.
Here’s how Pfizer stacks up across size, valuation, and profitability versus key peers.
| PFE | JNJ | MRK | ABBV | LLY | BMY | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 147.1 | 533.4 | 268.0 | 390.5 | 954.2 | 111.2 |
| Revenue ($ Bil) | 62.8 | 92.1 | 64.2 | 59.6 | 53.3 | 48.0 |
| PE Ratio | 15.0 | 21.2 | 14.1 | 163.5 | 69.1 | 18.4 |
| LTM Revenue Growth | 3.9% | 5.1% | 1.7% | 7.4% | 36.8% | 1.3% |
| LTM Operating Margin | 24.6% | 26.2% | 34.9% | 24.1% | 43.0% | 23.8% |
| LTM FCF Margin | 16.5% | 20.3% | 20.3% | 33.0% | -0.1% | 31.9% |
| 12M Market Return | 6.4% | 55.5% | 16.6% | 34.0% | 36.3% | -3.9% |
For more details on Pfizer, read Buy or Sell PFE Stock. Below we compare PFE’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 3.9% | 6.8% | -41.1% | 24.5% |
| JNJ | 5.1% | 4.3% | 6.5% | 1.6% |
| MRK | 1.7% | 6.7% | 1.4% | 21.7% |
| ABBV | 7.4% | 3.7% | -6.4% | 3.3% |
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| BMY | 1.3% | 7.3% | -2.5% | -0.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 24.6% | 23.3% | 7.1% | 36.7% |
| JNJ | 26.2% | 24.9% | 27.5% | 26.3% |
| MRK | 34.9% | 31.5% | 4.9% | 30.8% |
| ABBV | 24.1% | 21.1% | 24.9% | 32.4% |
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| BMY | 23.8% | 12.2% | 18.2% | 19.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 15.0 | 17.6 | 70.7 | 5.1 |
| JNJ | 21.2 | 35.4 | 10.4 | 22.9 |
| MRK | 14.1 | 15.6 | 691.5 | 19.0 |
| ABBV | 163.5 | 94.5 | 64.6 | 23.2 |
| LLY | 69.1 | 91.4 | 132.6 | 84.2 |
| BMY | 18.4 | -12.2 | 14.6 | 17.3 |
Still not sure about PFE stock? Consider portfolio approach.
Portfolios Over Individual Stock Picks
Individual stocks are unpredictable. A smart portfolio keeps you invested, limits downside shocks, and provides upside exposure
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.